$3396 | SAVE $599 | Single User
$6792 | SAVE $1,198 | Site License
$10187 | SAVE $1,798 | Enterprise License

EpiCast Report: Chronic Hepatitis B - Epidemiology Forecast to 2024

EpiCast Report: Chronic Hepatitis B - Epidemiology Forecast to 2024
[Lowest Price Guaranteed: $3,396]

Published by Global Data: 24 Dec 2015 | 17997 | In Stock
Related Topics: Hepatitis

Introduction

EpiCast Report: Chronic Hepatitis B - Epidemiology Forecast to 2024

Summary

The Hepatitis B Virus (HBV) can cause both acute and chronic liver disease. HBV is typically transmitted through contact with infectious blood or bodily fluid, including vertical transmission from mother to child at birth and transmission via sexual intercourse. Risk factors of chronic hepatitis B (CHB) include unprotected sex with an infected partner, men who have sex with men (MSM), intravenous drug injection (IDU), and a previous history of a sexually transmitted disease (STD). CHB has a well-established comorbidity association with hepatitis C virus (HCV) infection, hepatitis D virus (HDV) infection, human immunodeficiency virus (HIV) infection, and alcohol abuse. The disease often starts as asymptomatic in the acute infection phase, with symptoms beginning to present 30 to 180 days from infection. When symptoms develop, they present as nausea, vomiting, loss of appetite, flu-like symptoms, and jaundice. Severe cases of HBV infection increase the risk of developing liver cancer and cirrhosis.

GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of chronic hepatitis B (CHB) in the 8MM, from 10,557,407 cases in 2014 to 10,861,653 cases in 2024, at an Annual Growth Rate (AGR) of 0.29% in the forecast period. The distribution of diagnosed prevalent chronic hepatitis B cases in the 8MM was greater in men (7,379,948 cases, 69.90% in 2014) than in women (3,177,459 cases, 30.10% in 2014). This skew towards men was found to be consistent across all markets.

GlobalData’s epidemiological forecast for the diagnosed prevalent cases of CHB are supported by age- and sex-specific data obtained from country-specific studies published in peer-reviewed journals, in which the study populations are representative of the general population in the respective markets. The diagnosed prevalent cases are further segmented into ALT level, HBV DNA level, HBeAg status, cirrhosis status, and co-infection with hepatitis C and HIV, thus providing a comprehensive view of the characteristics of CHB patients in the 8MM. Additionally, GlobalData epidemiologists used the same methodology across the 8MM, which allows for a meaningful comparison of the forecast diagnosed incident cases and diagnosed prevalent cases of CHB in these markets.

Scope

- The Chronic Hepatitis B (CHB) EpiCast Report provides an overview of the risk factors and global trends of CHB in the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and China). It includes a 10-year epidemiological forecast for total and diagnosed prevalent cases of CHB segmented by sex and in these markets. The diagnosed prevalent cases of CHB are further segmented by hepatitis B virus (HBV) DNA level (<2000IU/mL, 2,000-20,000IU/mL, and >20,000IU/mL in the US and the 5EU, and <1000IU/mL, 1,000-10,000IU/mL, and >10,000IU/mL in Japan and China), alanine aminotransferase (ALT) level (=2 upper limit of normal [ULN] 2-5ULN and >5ULN), hepatitis e surface antigen (HBeAg) status, and the liver cirrhosis status.

- The CHB epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The CHB EpiCast report will allow you to -

- Develop business strategies by understanding the trends shaping and driving the global CHB market.

- Quantify patient populations in the global CHB market to improve product design, pricing, and launch plans.

- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CHB therapeutics in each of the markets covered.

- Identify the percentage of CHB diagnosed prevalent cases by various clinical segmentations.

Table of Contents
for EpiCast Report: Chronic Hepatitis B - Epidemiology Forecast to 2024

  • 1 Table of Contents

    1 Table of Contents 4

    1.1 List of Tables 6

    1.2 List of Figures 7

    2 Introduction 8

    2.1 Catalyst 8

    2.2 Related Reports 8

    2.3 Upcoming Related Reports 9

    3 Epidemiology 10

    3.1 Disease Background 10

    3.2 Risk Factors and Comorbidities 11

    3.3 Global Trends 12

    3.4 Forecast Methodology 14

    3.4.1 Sources Used 15

    3.4.2 Sources Not Used 24

    3.4.3 Forecast Assumptions and Methods 25

    3.5 Epidemiological Forecast of Chronic Hepatitis B (2014-2024) 31

    3.5.1 Diagnosed Prevalent Cases of Chronic Hepatitis B 31

    3.5.2 Age-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B 33

    3.5.3 Sex-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B 36

    3.5.4 Age-Standardized Diagnosed Prevalence of Chronic Hepatitis B 38

    3.5.5 Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by HBV DNA Level 39

    3.5.6 Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by ALT Level 41

    3.5.7 Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by HBeAg Status 42

    3.5.8 Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by Cirrhosis Status 43

    3.5.9 Diagnosed Prevalent Cases of Chronic Hepatitis B with Co-infection of HIV and Hepatitis C 45

    3.6 Discussion 46

    3.6.1 Epidemiological Forecast Insight 46

    3.6.2 Limitations of the Analysis 46

    3.6.3 Strengths of the Analysis 47

    4 Appendix 48

    4.1 Bibliography 48

    4.2 About the Authors 51

    4.2.1 Epidemiologists 51

    4.2.2 Reviewers 51

    4.2.3 Global Director of Therapy Analysis and Epidemiology 52

    4.2.4 Global Head of Healthcare 52

    4.3 About GlobalData 53

    4.4 About EpiCast 53

    4.5 Disclaimer 54

List Of Tables
in EpiCast Report: Chronic Hepatitis B - Epidemiology Forecast to 2024

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for Chronic Hepatitis B 12

Table 2: 8MM, Sources Used for the Diagnosed Prevalent Cases Forecast of Chronic Hepatitis B in the 8MM 15

Table 3: 8MM, Sources Used for HBV DNA Level 16

Table 4: 8MM, Sources Used for Chronic Hepatitis B by ALT Level 16

Table 5: 8MM, Sources Used for Chronic Hepatitis B HBeAg Status 17

Table 6: 8MM, Sources Used for Cirrhosis Status 18

Table 7: 8MM, Sources Used for HIV Co-infection 19

Table 8: 8MM, Sources Used for Hepatitis C Co-infection 20

Table 9: 8MM, Diagnosed Prevalent Cases of Chronic Hepatitis B, Both Sexes, All Ages, Select Years, 2014-2024 32

Table 10: 8MM, Age-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B, Ages ≥18 Years, N (Row %), 2014 34

Table 11: 8MM, Sex-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B, Ages ≥18 Years, N, 2014 37

Table 12: US and 5EU, Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by HBV DNA, Ages ≥18 Years, N, Both Sexes, 2014 40

Table 13: Japan and China, Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by HBV DNA, Ages ≥18 Years, N, Both Sexes, 2014 40

Table 14: 8MM, Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by ALT Level, Ages ≥18 Years, N, Both Sexes, 2014 42

Table 15: 8MM, Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by HBeAg Status, Ages ≥18 Years, N, Both Sexes, 2014 43

Table 16: 8MM, Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented Cirrhosis Status, Ages ≥18 Years, N, Both Sexes, 2014 44

Table 17: 8MM, Diagnosed Prevalent Chronic Hepatitis B Cases Segmented by Co-infection with HIV and Hepatitis C, Both Sexes, Ages ≥18 Years, N (% of Diagnosed Chronic Hepatitis B Cases), 2014 45

List Of Figures, Charts and Diagrams
in EpiCast Report: Chronic Hepatitis B - Epidemiology Forecast to 2024

1.2 List of Figures

Figure 1: 8MM, Diagnosed Prevalent Cases of Chronic Hepatitis B, Both Sexes, Ages ≥18 Years, Select Years, 2014-2024 33

Figure 2: 8MM, Age-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B, Ages ≥18 Years, Both Sexes, N, 2014 35

Figure 3: 8MM, Sex-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B, Ages ≥18 Years, N, 2014 38

Figure 4: 8MM, Age-Standardised Diagnosed Prevalence of Chronic Hepatitis B, Ages ≥18 Years, 2014 39

Additional Details

Publisher

Global Data

Publisher Information

Reference

17997 | GDHCER112-15

Number of Pages

55

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! EpiCast Report: Non-Hodgkin’s Lymphoma - Epidemiology Forecast to 2024
EpiCast Report: Non-Hodgkin’s Lymphoma - Epidemiology Forecast to 2024SummaryNon-Hodgkin’s Lymphoma ...
01 Jan 2016 by Global Data USD $3,396 (normally
USD $3,995)
More Info
SAVE 15% today! EpiCast Report: Pulmonary Arterial Hypertension - Epidemiology Forecast to 2024
EpiCast Report: Pulmonary Arterial Hypertension - Epidemiology Forecast to 2024SummaryPulmonary Arte...
01 Jan 2016 by Global Data USD $3,396 (normally
USD $3,995)
More Info
SAVE 15% today! EpiCast Report: Small Cell Lung Cancer - Epidemiology Forecast to 2024
EpiCast Report: Small Cell Lung Cancer - Epidemiology Forecast to 2024SummarySmall Cell Lung Cancer ...
01 Jan 2016 by Global Data USD $3,396 (normally
USD $3,995)
More Info
SAVE 15% today! EpiCast Report: Vasculitis - Epidemiology Forecast to 2024
EpiCast Report: Vasculitis - Epidemiology Forecast to 2024SummaryVasculitis is a group of heterogene...
01 Jan 2016 by Global Data USD $3,396 (normally
USD $3,995)
More Info
SAVE 15% today! EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024
EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024SummaryRSV is a...
23 Dec 2015 by Global Data USD $3,396 (normally
USD $3,995)
More Info
SAVE 15% today! EpiCast Report: Sjögren’s Syndrome - Epidemiology Forecast to 2024
EpiCast Report: Sjögren’s Syndrome - Epidemiology Forecast to 2024SummarySjögren’s syndrome (SS) is ...
09 Dec 2015 by Global Data USD $3,396 (normally
USD $3,995)
More Info
SAVE 15% today! EpiCast Report: Huntington’s Disease - Epidemiology Forecast to 2024
EpiCast Report: Huntington’s Disease - Epidemiology Forecast to 2024SummaryHuntington’s disease (HD)...
09 Dec 2015 by Global Data USD $3,396 (normally
USD $3,995)
More Info
SAVE 15% today! EpiCast Report: Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2024
EpiCast Report: Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2024SummarySystemic scle...
09 Dec 2015 by Global Data USD $3,396 (normally
USD $3,995)
More Info
SAVE 15% today! EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023
EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023SummaryC...
01 Dec 2015 by Global Data USD $3,396 (normally
USD $3,995)
More Info
SAVE 15% today! EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024
EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024SummaryPrimary brain cancer is defined a...
01 Dec 2015 by Global Data USD $3,396 (normally
USD $3,995)
More Info

This report is published by Global Data

Download Free Report Summary PDF

EpiCast Report: Chronic Hepatitis B - Epidemiology Forecast to 2024 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...